GAYO-FUNG LEAH M
No ORCID on file
· 42 papers in corpus
· active 2001-2004
Frequent coauthors
- BHAGWAT Shripad S. 42
- MCKIE Jeffrey A. 30
- CHAO Qi 30
- STEIN Bernd M. 30
- GANGLOFF Anthony R. 18
- RICE Kenneth D. 18
- ANDERSON DAVID WESLEY 12
- DOUBLEDAY MARY 12
- JALLURI RAVI KUMAR 12
- KOIS ADAM 12
2004
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-beta over ER-alpha. Methods are disclosed …
2004
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-beta over ER-alpha. Methods are disclosed …
2004
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-beta over ER-alpha. Methods are disclosed …
2004
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-beta over ER-alpha. Methods are disclosed …
2004
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-beta over ER-alpha. Methods are disclosed …
2004
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-beta over ER-alpha. Methods are disclosed …
2003
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-beta over ER-alpha. Methods are disclos…
2003
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-beta over ER-alpha. Methods are disclos…
2003
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-beta over ER-alpha. Methods are disclos…
2003
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-beta over ER-alpha. Methods are disclos…
2003
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-beta over ER-alpha. Methods are disclos…
2003
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-beta over ER-alpha. Methods are disclos…
2003
Compounds have the structure: including srereoisomers and pharmaceutically acceptable salts thereof; wherein a is 0, 1 or 2; A, B and C are independently CH, CR or N, wherein R is C1-6 alkyl; D is-(CH2)nC(=O)(CH2)m-; R1, R2, R3 are substitu…
2003
Compounds have the structure: including srereoisomers and pharmaceutically acceptable salts thereof; wherein a is 0, 1 or 2; A, B and C are independently CH, CR or N, wherein R is C1-6 alkyl; D is-(CH2)nC(=O)(CH2)m-; R1, R2, R3 are substitu…
2003
Compounds have the structure: including srereoisomers and pharmaceutically acceptable salts thereof; wherein a is 0, 1 or 2; A, B and C are independently CH, CR or N, wherein R is C1-6 alkyl; D is-(CH2)nC(=O)(CH2)m-; R1, R2, R3 are substitu…
2003
Compounds have the structure: including srereoisomers and pharmaceutically acceptable salts thereof; wherein a is 0, 1 or 2; A, B and C are independently CH, CR or N, wherein R is C1-6 alkyl; D is-(CH2)nC(=O)(CH2)m-; R1, R2, R3 are substitu…
2003
Compounds have the structure: including srereoisomers and pharmaceutically acceptable salts thereof; wherein a is 0, 1 or 2; A, B and C are independently CH, CR or N, wherein R is C1-6 alkyl; D is-(CH2)nC(=O)(CH2)m-; R1, R2, R3 are substitu…
2003
Compounds have the structure: including srereoisomers and pharmaceutically acceptable salts thereof; wherein a is 0, 1 or 2; A, B and C are independently CH, CR or N, wherein R is C1-6 alkyl; D is-(CH2)nC(=O)(CH2)m-; R1, R2, R3 are substitu…
2002
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-beta over ER-alpha. Methods are disclosed …
2002
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same:wherein R1, R2, R3, n and p are as defined here. Methods are…
2002
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-beta over ER-alpha. Methods are disclosed …
2002
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-beta over ER-alpha. Methods are disclosed …
2002
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same:wherein R1, R2, R3, n and p are as defined here. Methods are…
2002
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same:wherein R1, R2, R3, n and p are as defined here. Methods are…
2002
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same:wherein R1, R2, R3, n and p are as defined here. Methods are…